RIPE-KG · Version 1.1.0 · Resource
ripekg:work/RIPEWEC91F50567E370EA
https://w3id.org/ripe/ripe-kg/work/RIPEWEC91F50567E370EA
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
dcterms:title |
including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
rdf:type |
node1 |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
rdf:type |
rdfs:Resource |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
rdf:type |
owl:Thing |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
rdf:type |
prov:Entity |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
rdf:type |
ripe:WorkWork |